Simcere Pharmaceutical Group Ltd announced that Quviviq, a new anti-insomnia therapy developed with Idorsia, has received significant international acclaim at the World Sleep Congress in Singapore, with experts praising its effectiveness in improving both nighttime symptoms and daytime functioning.

• A real-world study showed patients experienced improved nighttime symptoms and enhanced daytime functioning over a 12-month period.
• The therapy, originally developed in Switzerland, was approved in China in June and is available in more than 10 countries and regions.
• David Neubauer, associate director of the Johns Hopkins Sleep Disorders Center, noted the new therapies target the hypothalamus, avoiding adverse effects of past medications, while Laura Palagini, psychiatrist at the University of Pisa, called it "a revolution."